Literature DB >> 8803622

Pulmonary infiltrates in the cancer patient. New approaches to an old problem.

G A Bergen1, J H Shelhamer.   

Abstract

A variety of etiologies may produce pulmonary infiltrates in a patient with cancer. Infectious etiologies, of an ever-increasing number, are always of paramount concern due to their high mortality in this patient population. Patients may be rendered immunosuppressed for prolonged periods of time and therefore are highly susceptible to infection. We present an overview of the many causes of pulmonary infiltrates in the cancer patient and an approach to diagnosis and treatment.

Entities:  

Mesh:

Year:  1996        PMID: 8803622     DOI: 10.1016/s0891-5520(05)70300-7

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  5 in total

1.  Contribution of quorum sensing to the virulence of Pseudomonas aeruginosa in burn wound infections.

Authors:  K P Rumbaugh; J A Griswold; B H Iglewski; A N Hamood
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

2.  Starvation selection restores elastase and rhamnolipid production in a Pseudomonas aeruginosa quorum-sensing mutant.

Authors:  C Van Delden; E C Pesci; J P Pearson; B H Iglewski
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

3.  Pseudomonas aeruginosa AlgR controls cyanide production in an AlgZ-dependent manner.

Authors:  William L Cody; Christopher L Pritchett; Adriana K Jones; Alexander J Carterson; Debra Jackson; Anders Frisk; Matthew C Wolfgang; Michael J Schurr
Journal:  J Bacteriol       Date:  2009-03-06       Impact factor: 3.490

4.  Optical monitoring and treatment of potentially lethal wound infections in vivo.

Authors:  Michael R Hamblin; Touqir Zahra; Christopher H Contag; Albert T McManus; Tayyaba Hasan
Journal:  J Infect Dis       Date:  2003-05-15       Impact factor: 5.226

Review 5.  Cell-to-cell signaling and Pseudomonas aeruginosa infections.

Authors:  C Van Delden; B H Iglewski
Journal:  Emerg Infect Dis       Date:  1998 Oct-Dec       Impact factor: 6.883

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.